CaltechAUTHORS
  A Caltech Library Service

Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection

Jiang, Yonghou and Duffy, Fergal and Hadlock, Jennifer and Raappana, Andrew and Styrchak, Sheila and Beck, Ingrid and Mast, Fred D. and Miller, Leslie R. and Chour, William and Houck, John and Armistead, Blair and Duvvuri, Venkata R. and Yeung, Winnie and Haglund, Micaela and Wallner, Jackson and Wallick, Julie A. and Hardy, Samantha and Oldroyd, Alyssa and Ko, Daisy and Gervassi, Ana and Murray, Kim M. and Kaplan, Henry and Aitchison, John D. and Heath, James R. and Sather, D. Noah and Goldman, Jason D. and Frenkel, Lisa and Harrington, Whitney E. (2021) Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. PLoS ONE, 16 (11). Art. No. e0259902. ISSN 1932-6203. PMCID PMC8598062. doi:10.1371/journal.pone.0259902. https://resolver.caltech.edu/CaltechAUTHORS:20210714-152527909

[img] PDF - Published Version
Creative Commons Attribution.

1MB
[img] PDF - Submitted Version
Creative Commons Attribution Non-commercial No Derivatives.

519kB
[img] MS Word (S1 Table. Human leukocyte antigen DRB1 allele by AT1R-Ab status amongst those with severe COVID-19) - Supplemental Material
Creative Commons Attribution.

16kB
[img] MS Excel (S1 File. Primary data for analysis of association between COVID-19 and AT1R-Ab status) - Supplemental Material
Creative Commons Attribution.

15kB
[img] MS Excel (S2 File. Primary data for analysis of association between AT1R-Ab status and anti-SARS-CoV-2 IgG levels amongst SARS-CoV-2 negative individuals) - Supplemental Material
Creative Commons Attribution.

10kB

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20210714-152527909

Abstract

Background: Coronavirus disease 2019 (COVID-19) is associated with endothelial activation and coagulopathy, which may be related to pre-existing or infection-induced pro-thrombotic autoantibodies such as those targeting angiotensin II type I receptor (AT1R-Ab). Methods: We compared prevalence and levels of AT1R-Ab in COVID-19 cases with mild or severe disease to age and sex matched negative controls utilizing multivariate logistic and quantile regression adjusted for comorbidities including hypertension, diabetes, and heart disease. Results: There were trends toward increased prevalence (50% vs. 33%, p = 0.1) and level of AT1R-Ab (median 9.8 vs. 6.1 U/mL, p = 0.06) in all cases versus controls. When considered by COVID-19 disease severity, there was a trend toward increased prevalence of AT1R-Ab (55% vs. 31%, p = 0.07), as well as significantly higher AT1R-Ab levels (median 10.7 vs. 5.9 U/mL, p = 0.03) amongst individuals with mild COVID-19 versus matched controls. In contrast, the prevalence (42% vs. 37%, p = 0.9) and level (both medians 6.7 U/mL, p = 0.9) of AT1R-Ab amongst those with severe COVID-19 did not differ from matched controls. Conclusions: These findings support an association between COVID-19 and AT1R-Ab, emphasizing that vascular pathology may be present in individuals with mild COVID-19 as well as those with severe disease.


Item Type:Article
Related URLs:
URLURL TypeDescription
https://doi.org/10.1371/journal.pone.0259902DOIArticle
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8598062/PubMed CentralArticle
https://doi.org/10.1101/2021.06.30.21259796DOIDiscussion Paper
ORCID:
AuthorORCID
Duffy, Fergal0000-0002-4675-0937
Hadlock, Jennifer0000-0001-6103-7606
Raappana, Andrew0000-0001-5248-4172
Beck, Ingrid0000-0001-7438-3209
Mast, Fred D.0000-0002-2177-6647
Chour, William0000-0003-1817-0123
Armistead, Blair0000-0001-9902-3955
Duvvuri, Venkata R.0000-0001-7356-338X
Yeung, Winnie0000-0001-8083-7449
Wallick, Julie A.0000-0002-4568-4704
Gervassi, Ana0000-0003-0321-5632
Kaplan, Henry0000-0001-9866-5200
Aitchison, John D.0000-0002-9153-6497
Heath, James R.0000-0001-5356-4385
Sather, D. Noah0000-0002-9128-172X
Goldman, Jason D.0000-0002-3825-6832
Frenkel, Lisa0000-0001-9566-8959
Harrington, Whitney E.0000-0002-0121-978X
Alternate Title:AT1R-Ab after SARS-CoV-2 infection
Additional Information:© 2021 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Received: June 11, 2021; Accepted: October 28, 2021; Published: November 17, 2021. This work was supported by Seattle Children’s Research Institute [to LF, WEH, NS, and JDA]; the National Institute of Allergy and Infectious Diseases [K08 AI135072 to WEH]; the Burroughs Wellcome Fund [CAMS 1017213 to WEH]; the Biomedical Advanced Research and Development Authority [HHSO10201600031C to JRH]; and the Swedish Medical Center Foundation [to JDG]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author Contributions: Conceptualization: Ana Gervassi, Henry Kaplan, John D. Aitchison, James R. Heath, Jason D. Goldman, Lisa Frenkel, Whitney E. Harrington. Data curation: Yonghou Jiang, Jennifer Hadlock, Ingrid Beck, Fred D. Mast, Leslie R. Miller, John Houck, Blair Armistead, Venkata R. Duvvuri, Winnie Yeung, Micaela Haglund, Julie A. Wallick, Kim M. Murray, Jason D. Goldman, Lisa Frenkel, Whitney E. Harrington. Formal analysis: Yonghou Jiang, Fergal Duffy, Whitney E. Harrington. Funding acquisition: James R. Heath, Jason D. Goldman, Whitney E. Harrington. Investigation: Yonghou Jiang, Fergal Duffy, Andrew Raappana, Sheila Styrchak, Ingrid Beck, Fred D. Mast, Leslie R. Miller, William Chour, Jackson Wallner, Samantha Hardy, Alyssa Oldroyd, Daisy Ko, John D. Aitchison, D. Noah Sather, Whitney E. Harrington. Methodology: Yonghou Jiang, Andrew Raappana, Sheila Styrchak, Ingrid Beck, William Chour, Venkata R. Duvvuri, Ana Gervassi, Henry Kaplan, D. Noah Sather, Lisa Frenkel, Whitney E. Harrington. Project administration: Jennifer Hadlock, Fred D. Mast, John Houck, Winnie Yeung, Micaela Haglund, Jackson Wallner, Julie A. Wallick, Kim M. Murray, Jason D. Goldman, Lisa Frenkel, Whitney E. Harrington. Resources: Lisa Frenkel. Supervision: John D. Aitchison, James R. Heath, D. Noah Sather, Jason D. Goldman, Whitney E. Harrington. Validation: Whitney E. Harrington. Visualization: Yonghou Jiang, Fergal Duffy, Blair Armistead. Writing – original draft: Yonghou Jiang, Fergal Duffy, Jason D. Goldman, Lisa Frenkel, Whitney E. Harrington. Writing – review & editing: Jason D. Goldman, Lisa Frenkel, Whitney E. Harrington. Competing interests: J.D.G. declared research support from Gilead, Lilly, and Regeneron, and Monogram Biosciences and served on advisory board for Gilead. The other authors declare no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Group:COVID-19
Funders:
Funding AgencyGrant Number
Seattle Childrens Research InstituteUNSPECIFIED
NIHK08 AI135072
Burroughs Wellcome FundCAMS 1017213
Biomedical Advanced Research and Development AuthorityHHSO10201600031C
Swedish Medical Center FoundationUNSPECIFIED
Issue or Number:11
PubMed Central ID:PMC8598062
DOI:10.1371/journal.pone.0259902
Record Number:CaltechAUTHORS:20210714-152527909
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20210714-152527909
Official Citation:Jiang Y, Duffy F, Hadlock J, Raappana A, Styrchak S, Beck I, et al. (2021) Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. PLoS ONE 16(11): e0259902. https://doi.org/10.1371/journal.pone.0259902
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:109806
Collection:CaltechAUTHORS
Deposited By: Tony Diaz
Deposited On:14 Jul 2021 18:15
Last Modified:10 Dec 2021 18:17

Repository Staff Only: item control page